Current Report Filing (8-k)
February 08 2019 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February
8, 2019
MYOS RENS TECHNOLOGY INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-53298
|
|
90-0772394
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
45 Horsehill Road,
Suite 106 Cedar Knolls, New Jersey
|
|
07927
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area
code
(973) 509-0444
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On January 30, 2019, MYOS
RENS Technology Inc. (the “
Company
”) received net proceeds of approximately $1.1 million from the sale of its
tax benefits through the New Jersey Technology Business Tax Certificate Transfer Program. This program provides a mechanism for
approved New Jersey technology and biotechnology companies to sell their unused net operating loss carryovers for cash. The Company
expects to use the proceeds from the sale for general working capital.
In accordance with General
Instruction B.2 of Form 8-K, the foregoing information shall not be deemed “filed” for the purposes of Section 18 of
the Exchange Act or otherwise subject to the liabilities of that section, nor shall such information, including Exhibit 99.1, be
deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MYOS RENS TECHNOLOGY, INC.
|
|
|
|
Dated: February 8, 2019
|
By:
|
/s/ Joseph Mannello
|
|
Name:
|
Joseph Mannello
|
|
Title:
|
Chief Executive Officer
|
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jul 2023 to Jul 2024